Literature DB >> 16170505

[Surgical therapy of intrahepatic cholangiocellular carcinoma].

H Lang1, G C Sotiropoulos, E Brokalaki, N R Frühauf, J Radü, A Paul, J Wohlschlaeger, H A Baba, M Malagó, C E Broelsch.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. Tumor resection is the treatment of choice, but so far the value of hepatic resection has not been well defined. We report results with an aggressive surgical approach for the treatment of this tumor entity. PATIENTS AND METHODS: Between April 1998 and June 2004, 54 liver resections were performed in 120 patients with ICC. In 24 patients, 39 additional procedures were performed: resection of hilar bifurcation (n=18), partial resection of diaphragm (n=6), vascular resection and reconstruction (n=15).
RESULTS: There were 30 R0, 21 R1, and three R2 resections. After R1/R2 resection and explorative laparotomy, the median survival times are 9 months and 6 months, respectively. Following R0 resection, the calculated median survival is 46 months, and the 1-, 3-, and 5-year survival rates are 83%, 58%, and 48%, respectively.
CONCLUSION: The presented data show that R0 resection leads to a significant prolongation of survival in patients with ICC. In contrast, incomplete tumor removal does not provide a survival benefit. These results justify an aggressive surgical approach to achieve a R0 resection. The low resectability rate of less than 50% underlines the need for improved preoperative staging.

Entities:  

Mesh:

Year:  2006        PMID: 16170505     DOI: 10.1007/s00104-005-1069-z

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  28 in total

1.  Surgical treatment of cholangiocarcinoma.

Authors:  F F Chou; S M Sheen-Chen; Y S Chen; M C Chen; C L Chen
Journal:  Hepatogastroenterology       Date:  1997 May-Jun

Review 2.  Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.

Authors:  M Shimoda; D G Farmer; S D Colquhoun; M Rosove; R M Ghobrial; H Yersiz; P Chen; R W Busuttil
Journal:  Liver Transpl       Date:  2001-12       Impact factor: 5.799

3.  Intrahepatic cholangiocarcinoma.

Authors:  K M Chu; E C Lai; S Al-Hadeedi; C E Arcilla; C M Lo; C L Liu; S T Fan; J Wong
Journal:  World J Surg       Date:  1997 Mar-Apr       Impact factor: 3.352

4.  A western surgical experience of peripheral cholangiocarcinoma.

Authors:  S V Berdah; J R Delpero; S Garcia; J Hardwigsen; Y P Le Treut
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

5.  The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases.

Authors:  M D'Angelica; Y Fong; S Weber; M Gonen; R P DeMatteo; K Conlon; L H Blumgart; W R Jarnagin
Journal:  Ann Surg Oncol       Date:  2003-03       Impact factor: 5.344

6.  Repeat hepatectomy for colorectal liver metastases.

Authors:  R Adam; H Bismuth; D Castaing; F Waechter; F Navarro; A Abascal; P Majno; L Engerran
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

7.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 8.  [Resections of recurrence in the liver of primary and secondary liver cancers].

Authors:  C Herfarth; U A Heuschen; W Lamade; T Lehnert; G Otto
Journal:  Chirurg       Date:  1995-10       Impact factor: 0.955

9.  Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes.

Authors:  S Roayaie; J V Guarrera; M Q Ye; S N Thung; S Emre; T M Fishbein; S R Guy; P A Sheiner; C M Miller; M E Schwartz
Journal:  J Am Coll Surg       Date:  1998-10       Impact factor: 6.113

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  7 in total

1.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 2.  [Liver resection and transplantation for hepatic tumors].

Authors:  H Lang; C E Broelsch
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

3.  GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma.

Authors:  Klaus J Schmitz; Hauke Lang; Ulrich H Frey; Georgios C Sotiropoulos; Jeremias Wohlschlaeger; Henning Reis; Atsushi Takeda; Winfried Siffert; Kurt W Schmid; Hideo A Baba
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

5.  Gross pathological classification of peripheral cholangiocarcinoma determines the efficacy of hepatectomy.

Authors:  Chun-Nan Yeh; Ta-Sen Yeh; Tse-Ching Chen; Yi-Yin Jan; Miin-Fu Chen
Journal:  J Gastroenterol       Date:  2012-09-25       Impact factor: 7.527

6.  Guidelines for palliative surgery of cholangiocarcinoma.

Authors:  H Witzigmann; H Lang; H Lauer
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

7.  Impact of Preoperative Three-Dimensional Computed Tomography Cholangiography on Postoperative Resection Margin Status in Patients Operated due to Hilar Cholangiocarcinoma.

Authors:  A Andert; P Bruners; C Heidenhain; F Ulmer; C D Klink; P H Alizai; C Kuhl; U P Neumann; M Binnebösel
Journal:  Gastroenterol Res Pract       Date:  2017-08-16       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.